MDxHealth SA

MDxHealth SA is a leading molecular diagnostics company that develops and commercializes advanced tests for cancer assessment and personalized treatment. The company was founded in 2003 as OncoMethylome Sciences and changed its name to MDxHealth in 2010. The company is headquartered in Herstal, Belgium, with a US subsidiary in Irvine, California.

MDxHealth has a market capitalization of about $0.5B as of April 11, 2023, according to Yahoo Finance. The company is listed on the Euronext Brussels exchange under the ticker symbol MDXH.

The company's vision is to revolutionize the management of urologic cancers by providing accurate and actionable information to patients and physicians. The company's main products are SelectMDx and ConfirmMDx, two non-invasive urine tests that help detect and monitor prostate cancer.

SelectMDx is a liquid biopsy test that measures the expression of two biomarkers associated with aggressive prostate cancer. The test helps identify patients at high risk of having clinically significant prostate cancer who may benefit from a prostate biopsy. ConfirmMDx is a tissue-based test that analyzes the methylation status of three genes involved in prostate cancer. The test helps rule out false-negative biopsy results and avoid unnecessary repeat biopsies.

MDxHealth also offers other tests for bladder, kidney, and colorectal cancers, as well as services for pharmaceutical and biotech companies, such as biomarker discovery, assay development, and clinical trial support.

Foundation: 2003

Headquarters: Herstal, Belgium

Website: https://mdxhealth.com/